Company and Stock Identity

How Eli Lilly and Company Connects to the Public Market

Company structure
Public company
Market access
Direct listing: NYSE: LLY.
Stock name
ELI LILLY & Co
Ticker and exchange
NYSE: LLY
Research focus
This group asks how far a partnership actually went. Lilly is worth watching because it is not only buying AI, it runs a programme called TuneLab that hands AI capability to other biotech companies, which makes it a supplier as well as a customer. That changes the question: ask who gets access, on what terms, and what Lilly gets back. There is a catch before you research this one. Both Lilly items sit only on a newswire host that blocks automated reading, and Lilly's own news and investor pages block it too, so this desk has not read either announcement and has published no brief on them. A Lilly filing is a better place to look for terms than a press page.

The federal filer record for ELI LILLY & Co, read on 2026-11-07, gives the ticker LLY on the New York Stock Exchange, central index key 0000059478, incorporation in Indiana, and a head office at Lilly Corporate Center, Indianapolis, Indiana 46285. Its newest filings in that record are a quarterly report filed 29 October 2026 and a run of insider ownership forms through 4 November 2026. The record also lists two earlier filer names, LILLY ELI & CO until 25 October 2019 and LILLY ELI & CO ET AL in 1994, which are filing labels rather than a change of ownership. No change of control was found. The main Lilly website, its news page and its investor site all refused this desk on 2026-11-07, answering 403 Forbidden or breaking the request; the United States careers site is the one Lilly host that opened. Checked on 2026-11-07.

Dated Market Snapshot

Nov 13, 2026

Last price
$1,444.63
Change
+1.34%
Previous close
$1,425.55
52-week high / low
$1460/$850.51
Market cap
1,359,028,494,134

Automated from Nasdaq. Check the exchange or investor-relations page for the current price.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... Chai Discovery ... Company source

Chai Discovery raises 400 million dollars at a 3.8 billion dollar valuation

Chai Discovery said on 14 July 2026 that it raised 400 million dollars at a stated valuation of 3.8 billion dollars, in a round led by Index Ventures and Kleiner Perkins alongside Sequoia Capital, Dimension and other investors. The company says the money will expand the compute, data and research behind its models, speed up product development and put the technology in front of more scientists, and that its latest model, Chai-3, is being adopted across Eli Lilly, Pfizer and Novartis.

Why it matters: Spending a round this size on compute and data rather than on a laboratory is the clearest statement of what Chai Discovery is: a model company selling to drug companies, not a drug company. For a research team that is good news on access and bad news on alignment, because the vendor's incentive is adoption across many partners rather than one programme succeeding. A 3.8 billion dollar valuation on no approved product also means the next round depends on partners renewing, so ask about contract length before building a workflow on it.

... Chai Discovery ... Company source

Novartis gets access to Chai Discovery's antibody design models

Chai Discovery announced on 13 July 2026 that Novartis will get access to its AI models, including Chai-3, to support therapeutic antibody discovery across multiple targets. Financial terms were not disclosed, and the announcement gives no number of programs or milestones. Fiona Marshall, Novartis's president of biomedical research, is quoted saying AI is already reshaping how the company discovers medicines and that applying advanced models to problems like antibody design lets it explore a broader range. Joshua Meier, Chai's co-founder and chief executive, is quoted calling it a significant step forward. The announcement also names Pfizer and Eli Lilly as earlier users of Chai's models.

Why it matters: This is an access agreement, which is the lightest kind of deal in this field. A large drug company can hand a model to a research group, try it on a few targets and walk away without ever announcing that it stopped. Nothing here is a result, and nothing here involves a patient. What it does tell a biologics team is that the design models cleared whatever internal review Novartis runs before outside software touches real programs, and that Chai now has three of the largest drug companies on that list. Treat the names as a signal about the software being taken seriously, not as evidence that it works.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: The United States careers site, titled Find Your Career with Eli Lilly, is the one Lilly page that opened on 2026-11-07. It says research and development is "nearly 25% of our workforce" and puts manufacturing and operations roles forward alongside it, naming craft apprenticeship and operator positions. It gives the corporate address as Indianapolis, Indiana 46285 and states no total employee count and no number of open roles. It names no AI or data science roles at all, which is worth noticing at a company building an AI programme.

Qualification signal: With a quarter of the workforce in research and development, the pull here is scientific rather than software. For AI work, the experience that counts is having put a model in front of people who must defend a result, and having it survive that. Because the careers site names no AI or data science roles, do not assume from a title: ask whether a role sits inside a research unit, inside manufacturing, or inside the TuneLab programme, because those are three different jobs.

Check current roles at Eli Lilly and Company. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Research and development leaders, clinical development teams, business development staff, and investors tracking where AI partnerships lead
Primary use case
Sponsor, license, or partner on AI research, molecule design, and trial measurement in drug development
Typical deployment
Drug developer. AI arrives through a research collaboration, a licence, or a tool used inside a clinical trial.

Evidence questions

  • What stage did the agreement reach, and were any payments or milestones disclosed?
  • Which programs or molecules does the AI work actually touch?
  • Has anything from the collaboration reached a clinical endpoint rather than a press release?

Regulatory and workflow questions

  • If AI produced a measurement used in a trial, has a regulator accepted that measurement?
  • Which regulatory submissions, if any, depend on the AI work?
  • Who is responsible for the quality of an AI-generated result inside a trial record?

Data and contract questions

  • Whose data trained the model, and what did the drug company contribute?
  • Who owns a molecule or design the collaboration produces?
  • What happens to the shared data if the collaboration ends?

Evidence and Regulation

FDA Clearances on Record

No clearance is linked in this directory. That is not automatically a mark against the company. Some products support the people doing the work instead of reading a patient image or signal themselves.

First-Hand Sources